Xeris Biopharma Holdings, Inc.
$8.70
The Read: XERS's stock has historically declined sharply despite strong earnings and revenue growth due to investor concerns over patent infringement litigation threatening its core drug Recorlev and its profit margins.
Price
Overlays
Panel
XERS
Hover to view data
No Data